Company Overview and News

RCR notches profit boost

Engineering contractor RCR Tomlinson has reported a big boost in profits for the half-year, propelled by a near doubling in revenue as the company increases its stake in the renewable energy sector.
Upvote Downvote

Demand for mining services ramps up (Part 2)

Improved commodity prices led to an increase in mining activity, meaning the expertise of the country’s mining services contractors was in growing demand.
Upvote Downvote

Goldsworthy, Skira to Power board

Former Rio Tinto executive Denise Goldsworthy and former Water Corporation chair Eva Skira have been appointed directors of power pole and wire operator Western Power, replacing Northern Australian Infrastructure Facility chair Sharon Warburton and former state politician George Cash.
Upvote Downvote

RCR increases infrastructure funding by $150m

Engineering and infrastructure firm RCR Tomlinson has announced that it has extended its bank guarantee from $195 million to $295 million and has received approval for insurance bonding facility increases of $50 million, a total of $150 million in increased funding.
Upvote Downvote

RCR in $33m conveyor deal for FMG

Engineering contractor RCR Tomlinson has secured a $33 million contract to design and construct a 5 kilometre relocatable conveyor system for Fortescue Metals Group.
Upvote Downvote

RCR in $33m conveyor build for FMG

Engineering and infrastructure company RCR Tomlinson has secured a $33 million contract to design and construct a 5 kilometre relocatable conveyor system for Fortescue Metals Group that will be trialled at its Cloudbreak mine in the Pilbara.
Upvote Downvote

RCR wins $33m innovation contract with Fortescue

Fortescue Metals Group has awarded RCR Tomlinson a $33 million contract to design, manufacture and construct a five-kilometre relocatable conveyor system for its iron ore operations in the Pilbara.
Upvote Downvote

Whittens wins contract at Pilgangoora lithium project

Whittens has secured its sixth contact for 2017 with RCR Tomlinson at Pilbara Minerals’ Pilgangoora lithium-tantalum project in Western Australia.
Upvote Downvote

Whittens wins Pilgangoora work

Local construction company Whittens has won a $10 million contract for work on Pilbara Minerals’ Pilgangoora lithium project.
Upvote Downvote

First Solar Wins Deal to Supply 241 MW Modules in Australia

2017-08-15 zacks
First Solar Inc. (FSLR - Free Report) has won a contract from RCR Tomlinson Ltd to supply solar modules with a total capacity of 241 megawatt (MW). Per the deal, this company will act as the engineering, procurement and construction contractor for Australian renewable energy group, Edify Energy’s Daydream solar project, with a capacity of 180.7 MW and 60.2 MW Hayman solar project in Queensland, Australia.
Upvote Downvote

RCR wins $315m in solar work

RCR Tomlinson has won two contracts worth a combined $315 million for the construction and maintenance of two solar farms in Queensland for Edify Energy.
Upvote Downvote

Lithium Miners News For The Month Of July 2017

2017-07-27 seekingalpha
Lithium spot and contract price news - No change from last month; up 9.81% in the past year.
Upvote Downvote

Pilbara Minerals finalises Pilgangoora contracts

Pilbara Minerals has signed-off four major contracts for its Pilgangoora lithium project, with RCR Tomlinson, NRW Holdings, Action Industrial Catering and the Njamal traditional owners winning the lion’s share of the work.
Upvote Downvote

RCR loses appeal in eight-year court fight

RCR Tomlinson has lost the latest round in a long-running legal action against a former executive who was dismissed in 2009, and will pay nearly $300,000 in retirement benefits after an appeal by the company was dismissed.
Upvote Downvote

Contractors boosted by mine projects

Local contractor Primero Group is set to win its third major contract on a mining project this year while RCR Tomlinson has geared up to supply Rio Tinto’s new iron ore mine.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...